anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Degenerative Cervical Myelopathy (DCM) is the functional derangement of the spinal cord resulting from vertebral column spondylotic degeneration. Typical neurological symptoms of DCM include gait imbalance, hand/arm numbness, and upper extremity dexterity loss. Greater spinal cord compression is believed to lead to a higher rate of neurological deterioration, although clinical experience suggests a more complex mechanism involving spinal canal diameter (SCD). In this study, we utilized machine learning clustering to understand the relationship between SCD and different patterns of cord compression (i.e. compression at one disc level, two disc levels, etc.) to identify patient groups at risk of neurological deterioration. 124 MRI scans from 51 non-operative DCM patients were assessed through manual scoring of cord compression and SCD measurements. Dimensionality reduction techniques and k-means clustering established patient groups that were then defined with their unique risk criteria. We found that the compression pattern is unimportant at SCD extremes (≤14.5 mm or > 15.75 mm). Otherwise, severe spinal cord compression at two disc levels increases deterioration likelihood. Notably, if SCD is normal and cord compression is not severe at multiple levels, deterioration likelihood is relatively reduced, even if the spinal cord is experiencing compression. We elucidated five patient groups with their associated risks of deterioration, according to both SCD range and cord compression pattern. Overall, SCD and focal cord compression alone do not reliably predict an increased risk of neurological deterioration. Instead, the specific combination of narrow SCD with multi-level focal cord compression increases the likelihood of neurological deterioration in mild DCM patients.
PURPOSE:To prepare the titled carcinostatic substance, by culturing specific microbial strain, removing proteins from the cultured liquid, and concentrating the substance by ultrafiltration. CONSTITUTION:Bacterial strain belonging to Fusobacterium genus and capable of producing carcinostatic substance TF-300-2, e.g. Fusobacterium nucleatum TF- 031 (FERM-P No.5077, ATCC-31647), is cultured under anaerobic conditions at about 30-42 deg.C for about 1-5 days, and the microbial cells are removed from the cultured liquid. A hydrophilic organic solvent (e.g. ethanol) is added to the supernatant liquid, the produced precipitate is separated, and the active fraction  is collected by adjusting the pH of the solution. The active fraction is treated  with an enzyme to effect the removal of proteins, concentrated and desalted by  the ultrafiltration (fractionated molecular weight; about 50,000-200,000), and  dried to obtain the carcinostatic substance TF-300-2.
Grup 2 - Hyperinflation with Mechanical ventilator: Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the increase in inspiratory pressure ventilator .
Sociodemographic and clinical data of the patients who will be operated between 08:00 PM -01:00 AM will be recorded. The total amount of antiemetic,the time of first antiemetic use, and the VAS scores at the postoperative 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours will also be recorded.
Photodynamic therapy (PDT) is widely used in the treatment of superficial skin cancer. It has an excellent cosmetic outcome, and it could be considered the first-line therapy for Actinic keratosis (AK). In PDT incubation time is required so that the photosensitizer can be converted to PpIX. The recommended treatment regimen of PDT requires a relatively long incubation time with ALA (4 hours) and MAL (3 hours) before illumination. Theoretically, ablative fractional laser (AFL) pre-treatment may facilitate the penetration and distribution of topically applied drugs, since the ablated laser holes extend into the dermis, thereby possibly acting as channels for drug uptake. However, knowledge on the optimal photosensitizer incubation time for AFL-PDT is limited. The objectives of this study were to compare the efficacy, recurrence rate, cosmetic outcome, and safety between AFL-PDT with 2 and 3hours of incubation vs. conventional MAL-PDT in patients with facial and scalp AK.
FIELD: medicine. ^ SUBSTANCE: invention refers to an oral composition marking procedure. A marking procedure involves surface distribution of a discolouring oxide and laser scanning of said oral composition surface with wave lengths 200 nm to 1100 nm and average force 0.1 V to 50 V in an interval whereat said composition surface is almost non-etched to agglomerate discolouring oxide particles to induce discoloration. The discolouring oxide applied in the given invention represents titanium dioxide, a yellow iron oxide (III) or red iron oxide (III). ^ EFFECT: marking procedure is high-yield and ensures the easy-to-identify oral compositions, such as drugs and foodstuff with no quality damage. ^ 24 cl, 4 dwg, 4 tbl, 16 ex
Systems and methods for fully-automated contact-less biometric measurement include receiving a stream of image frames from an internet capable device. Frame data is extracted from the stream of image frames. A predictive load balancer selects a worker server based on a load prediction. An interface delivery server communicates the frame data from the internet capable device to the worker server. A set of patient face images captured by the frame data are extracted. A facial recognition machine learning model determines a patient identity associated with the set of patient face images of the frame data. A shared memory system stores the set of patient face images. The worker server determines biometric measurements based on the set of patient face images in the shared memory system using independent biometric data processing pipelines with shared access to the shared memory system for inter-process communication.
The invention relates to compounds of a general formula <FORM:0987050/C2/1> in which R represents a lower alkyl radical and X a hydrogen atom or the residue of a physiologically acceptable inorganic or organic base, e.g. hydroxides of lithium, sodium or magnesium, ethanol and diethanol amines, morpholine or methylglucamine. Compounds claimed per se are succinic acid-mono-2,4,6-triiodo-3-amino-N-methyl, and -N-ethyl anilides and sodium salts thereof.  The compounds may be prepared by reacting a 3-nitro-N-alkylaniline with succinic anhydride and the nitro group reduced and the nucleus iodinated or subjecting succinic acid-mono-3-amino anilide to nuclear iodination and alkylating the product on the N atom.  In an example a mixture of 3-nitro-N-methyl aniline and succinic anhydride are heated for five or six hours to produce succinic-mono-3-nitro-N-methyl anilide which is subjected to hydrogenation under pressure with Raney nickel catalyst to form succinic acid mono-3-amino-N-methyl anilide which is iodinated by the addition of KICl2 solution and the precipitated iodination product succinic acid-mono-2,4,6-triiodo-3-amino-N-methyl anilide separated off.ALSO:X-ray contrast media comprise at least one compound of a general formula <FORM:0987050/A5-A6/1> in which R represents a lower alkyl radical, X is H or a physiologically acceptable salt thereof with an inorganic or organic base.  Specified active compounds are succinic acid-mono-2,4,6-triiodo-3-amino-N-methyl and -ethyl anilides with starch paste, sugar, syrup and the sodium salt with sesame oil filled into gelatine capsules.
Oraqix used at the recommended doses is not likely to cause toxic plasma levels of lidocaine or prilocaine. However, if other local anesthetics are administered at the same time, e.g. topically or by injection, the toxic effects are thought to be additive and could result in an overdose with systemic toxic reactions. There is generally an increase in severity of symptoms with increasing plasma concentrations of lidocaine and/or prilocaine. Systemic CNS toxicity may occur over a range of plasma concentrations of local anesthetics. CNS toxicity may typically be found around 5000 ng/mL of lidocaine; however a small number of patients reportedly may show signs of toxicity at approximately 1000 ng/mL. Pharmacological thresholds for prilocaine are poorly defined. Central nervous system (CNS) symptoms usually precede cardiovascular manifestations. The plasma level of lidocaine observed after the maximum recommended dose (5 cartridges) of Oraqix in 11 patients exposed over 3 hours ranged from 157 to 552 ng/mL with a mean of 284 ng/mL ± 122 SD. The corresponding figure for prilocaine was 53-181 ng/mL with a mean of 106 ± 45 SD. [See Clinical Pharmacology (12.3)].

Systemic adverse effects of lidocaine and/or prilocaine are manifested by central nervous system and/or cardiovascular symptoms.

Clinical symptoms of systemic toxicity include CNS excitation and/or depression (light-headedness, hyperacusis, visual disturbances, muscular tremors, and general convulsions). Lidocaine and/or prilocaine may cause decreases in cardiac output, total peripheral resistance and mean arterial pressure. These changes may be attributable to direct depressant effects of these local anesthetic agents on the cardiovascular system. Cardiovascular manifestations may include hypotension, bradycardia, arrhythmia, and cardiovascular collapse.
PURPOSE: Selinexor is a first-in-class, oral selective-inhibitor-of-nuclear-export, granted accelerated approval by FDA (2019) for relapsed and refractory multiple myeloma (RRMM). We sought to quantitatively summarize the selinexor efficacy and safety in RRMM.
METHODS: We searched PubMed, EMBASE, CENTRAL, clinicaltrial.gov, and google scholar, until May 2023, studies about selinexor use in RRMM. The outcome measures of interest were primarily efficacy outcomes, in addition to safety outcomes. Random-effect model analyses were performed, at statistical significance of P<0.05, using the RevMan software.
RESULTS: Meta-analyses of eleven included clinical trials yielded a significant 56.21% overall clinical benefit, 46.91% overall response, 4.89% complete response, 23.41% very good partial response, 24.68% partial response, and 28.06% stable disease rates with selinexor. Due to safety reasons, selinexor caused significant increase in discontinuation rate, 16.80%. Subgroup analyses demonstrated higher efficacy with selinexor plus dexamethasone and proteasome inhibitor combinations than with selinexor alone. The multiple myeloma type, high cytogenetic risk, refractory state, and advanced disease state did not affect performance. Risk of selection, performance, and detection biases were unclear in the included trials.
CONCLUSION: Selinexor led to significant positive responses with an acceptable safety profile in RRMM patients, despite higher rates of safety-related discontinuations. Selinexor-based combinations further enhanced response.
Apply LIDODERM to intact skin to cover the most painful area. Apply up to three patches, only once for up to 12 hours within a 24-hour period. Patches may be cut into smaller sizes with scissors prior to removal of the release liner. (See HANDLING AND DISPOSAL) Clothing may be worn over the area of application. Smaller areas of treatment are recommended in a debilitated patient, or a patient with impaired elimination. 

If irritation or a burning sensation occurs during application, remove the patch (es) and do not reapply until the irritation subsides.

When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.
The invention discloses an early gastric adenocarcinoma primary cells single-stranded DNA aptamer and a preparation method thereof. The gene sequences of the early gastric adenocarcinoma primary cells single-stranded DNA aptamer are respectively: SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4 and SEQ ID No. 5. The early gastric adenocarcinoma primary cells single-stranded DNA aptamer can be applied in detecting early gastric adenocarcinoma, can be applied in preparing detection reagents for early gastric adenocarcinoma and can also be applied in preparing drugs for the treatment of gastric adenocarcinoma.
OBJECTIVES: To elucidate the association between genetic variants and the risk of GCA via large-scale genome-wide association studies (GWAS). In addition, to assess the causal effect of a specific molecule by employing the obtained GWAS results as genetic epidemiological tools.
METHODS: We applied additional variant quality control to the publicly available GWAS results from the biobanks of the UK (UKBB) and Finland (FinnGen), which comprised 532 cases vs 408 565 controls and 884 cases vs 332 115 controls, respectively. We further meta-analysed these two sets of results. We performed two-sample Mendelian randomization (MR) to test the causal effect of low-density lipoprotein (LDL) cholesterol on the risk of GCA.
RESULTS: The MHC class II region showed significant associations in UKBB, FinnGen and the meta-analysis. The VLDLR region was associated with GCA risk in the meta-analysis. The T allele of rs7044155 increased the expression of VLDLR, decreased the LDL cholesterol level and decreased the disease risk. The subsequent MR results indicated that a 1 s.d. increase in LDL cholesterol was associated with an increased risk of GCA (odds ratio 1.21, 95% CI 1.01-1.45; P = 0.04).
CONCLUSIONS: Our study identified associations between GCA risk and the MHC class II and VLDLR regions. Moreover, LDL cholesterol was suggested to have a causal effect on the risk of developing GCA.
The invention discloses a Chinese herbal medicine compound preparation used for treating slipped disk. The preparation comprises active components and auxiliary materials. the preparation is characterized in that the active components comprise, by weight, 20-40 parts of Shensi monkshood root, 20-40 parts of Taipei monkshood root, 20-40 parts of ovateleaf knotweed rhizome, 20-40 parts of henry rhodiola herb, 20-40 parts of wild watermelon, 20-40 parts of cinnamon, 20-40 parts of dried ginger, 20-40 parts of camphor, 20-30 parts of angelica archang lica, 20-30 parts of red berry jackinthepulpit tuber, 20-30 parts of red peony root, and 20-40 parts of Gugusan powder. The slipped-disk-treating Chinese herbal medicine compound preparation provided by the invention comprises a plurality of Chinese herbal medicine plant crude drugs such as alkaloids and musk ketone with functions of meridian warming, vein unblocking, blood circulation activating, and pain relieving. The preparation is grinded without high temperature, and is directly blended into a paste by using honey. Therefore, medicine components with certain treatment effects can be effectively protected from damage. With the preparation, symptoms can be treated, and damage to healthy qi is not caused. The preparation is finely formulated, and a synergetic effect is provided.
Safety and effectiveness in children have not been established. The clearance of dopamine is affected by age (as much as 2 fold greater in children under 2 years of age), renal and hepatic function (decreasing by 2 fold in the presence of either). In younger children, particularly neonates, clearance is highly variable. Newborn infants may be more sensitive to the vasoconstrictive effects of dopamine.

The most consistent effects of dopamine in 57 publications (between the years 1966 through 1997) were increases in systolic and mean arterial pressure. Renal function was variably affected, except that in a single publication renal function was preserved in the face of treatment with indomethacin. No consistent effect on heart rate was described. Because of the variability of clearance, especially in the neonate and newborn, low doses of dopamine and slow deliberate titration should be employed (see DOSAGE and ADMINISTRATION).
BACKGROUND: Counselling adolescents with chronic medical conditions (CMCs) can be challenging regarding suitable interviewing skills and clinicians' attitudes toward the patient. Successful communication can be a key element of treatment. Motivational Interviewing (MI) is broadly applicable in managing behavioural problems and diseases by increasing patient motivation for lifestyle changes. However, data concerning the applicability, feasibility and implementation of MI sessions in everyday practice are missing from the physicians' point of view.
METHOD: The present study was conducted as a mixed methods design. Twenty paediatricians were randomized to a 2-day MI course followed by MI consultations. Data were collected through a questionnaire one year after MI training. Factors for effective training and possible barriers to successful use of MI were examined.
RESULTS: Completed questionnaires were returned by 19 of 20 paediatricians. The paediatricians' experiences with MI demonstrate that MI is regarded as a valuable tool when working with adolescents with CMCs. 95% of all respondents reported that they found MI education necessary for their clinical work and were using it also outside the COACH-MI study context. 73.7% percent saw potential to strengthen the connection to their patients by using MI. The doctors were already using more MI conversation techniques after a 2-day MI course. Obstacles were seen in the short training, the lack of time and missing undisturbed environment (interruptions by telephone, staff, etc.) during clinical flow.
CONCLUSIONS: MI techniques are not yet a regular part of medical training. However, a 2-day MI course was rated effective and provided a lasting impact by physicians caring for children and adolescents with chronic medical conditions (CMCs), although booster sessions should be offered regularly.
TRIAL REGISTRATION: The study was registered in the German Clinical Trials Register (DRKS00014043) on 26/04/2018.
Disclosed herein are immune effector cells for use in adoptive cell transfer that have chemically- or genetically-inhibited PDHB (Pyruvate dehydrogenase E1 subunit beta) expression or activity. Also disclosed are methods of inhibiting or ablating PDHB expression in immune effector cells ex vivo and methods of using these cells to treat subjects with cancer. In some embodiments, the immune effector cells are further treated with a TIMS inhibitor or gendtically engineered to ablate TIM3 expression. In some embodiments, the immune effector cells are further treated with a LAGS inhibitor or genetically engineered to ablate LAG3 expression. In some cases, the PDHB gene is disrupted by insertion of the gene encoding the chimeric receptor into the PDHB gene loci of the cell. Therefore, disclosed herein is a chimeric cell expressing a chimeric receptor.
BACKGROUND: Whole genome sequencing (WGS) of respiratory viruses from rapid antigen tests (RAT-WGS) is a novel approach to expanding genomic surveillance of respiratory infections. To date however, there are limited data on the genomic stability of these viruses on RATs. In this study, we investigated the effect of storage conditions and nucleic acid preservatives on the ability to enhance stability and improve recovery of respiratory virus genomes from RATs.
METHODS: A mixture of common respiratory viruses was used to inoculate RATs at different environmental temperatures (4°C, 20°C and 36°C), with two preservative reagents (RNALater and DNA/RNA shield) Nucleic acid was extracted from RATs at two different timepoints (72 h and seven days) and subject to real-time multiplex respiratory PCR to detect a range of respiratory viruses. WGS was performed using target-enrichment with the TWIST Comprehensive Viral Research Panel. Defined metrics from an automated in-house bioinformatic pipeline were used to assess and compare viral genome recovery under different conditions.
RESULTS: Nucleic acid degradation (indicated by relative change in PCR cycle threshold and WGS-based metrics) was most notable at 20 °C and 36 °C. Storage in either RNALater or DNA / RNA shield improved genome recovery for respiratory viruses across all temperature conditions, although this was most pronounced for RNALater. Subtyping of Influenza viruses demonstrated the applicability of RAT-WGS in downstream genomic epidemiological surveillance.
CONCLUSIONS: Under simulated conditions, RAT-WGS demonstrated that (i) viral genomes were generally stable at 4°C at 72 h and 1 week, (ii) RNALater has a more significant preservation of nucleic acids compared to DNA/RNA Shield and (iii) genome recovery can be achieved using a sequencing depth of 500,000 reads per sample in RNALater, across all respiratory viruses and conditions.
The current study attempts to design a short-term intervention aimed at stabilizing decompensate personality disorder patients in hospitalization. The study is structured as a pilot study, thus will enroll 20 patients only. Patients, upon being hospitalized and after signing the consent to participate in the study, will be randomized to two groups: The first will be treated by the novel, LOOP, concept' the other will be TAU, as routinely done with PersDis patients in the investigators facility. The outcome parameters will be changes in series of questionnaires filled upon being enrolled and at the end of the intervention. Another outcome parameter will be readmission rates in the post-intervention period (3 months).

The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the "place" where the investigators experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes.
The present invention relates to a co-culture method of  Sphingomonas  sp. bacterial strain and  Aspergillus  sp. fungus strain, in which the novel  Sphingomonas  sp. bacterial strain KMK-001 is cultured in a liquid medium and the novel  Aspergillus  sp. strain KMC-901 separately cultured in another liquid medium is added to the above culture solution, a novel glionitrin biosynthesized therefrom and a pharmaceutical composition comprising the said glionitrin or its pharmaceutically acceptable salt as an active ingredient. The glionitrin herein has strong cytotoxic effect on cancer cells and has antibiotic effect on 10 pathogenic bacteria including the novel  Sphingomonas  sp. bacterial strain KMK-001, so that it can be effectively applied in antibiotics or anti-cancer agents.
PROBLEM TO BE SOLVED: To obtain a medicine excellent in therapeutic effect on diabetic mellitus and having no side effect by combining an insulin resistance improving agent and an appetite suppressing agent. SOLUTION: This medicine comprises combination of an insulin resistance improving agent and an appetite suppressing agent. Preferably the insulin resistance improving agent is a compound shown by the formula [R is a (substituted) hydrocarbon group or a heterocyclic group; Y is a group of CO or CH(OH) or the like; (m) is 0 or 1; (n) is 0-2; X is CH or N; A is a bonding group or a 1-7C bifunctional hydrocarbon; Q is O or S; R1 is H or an alkyl; L and M are each H or a bonding group] or its salt (preferably pioglitazone hydrochloride). Preferably the appetite suppressing agent is a central appetite suppressing agent (preferably mazindol). Preferably the medicine is a prophylactic and/or therapeutic agent for non-insulin-dependent diabetes, a diabetic complication or a glucose tolerance disorder.  The dose of the medicine is 0.1-500 mg/day in the case of the insulin resistance improving agent.